The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I):
and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.
The present invention is directed to thienopyrimidine compounds of formula (I):
and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.
The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
本发明提供了新型的取代异噁唑化合物、制药组合物、治疗用途和制备方法。
US7960552B2
申请人:——
公开号:US7960552B2
公开(公告)日:2011-06-14
[EN] FARNESOID X RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR FARNÉSOÏDE X
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2008051942A2
公开(公告)日:2008-05-02
[EN] The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same. [FR] L'invention concerne des nouveaux composés d'isoxazole substitués, des compositions pharmaceutiques, des utilisations thérapeutiques et des procédés pour préparer ceux-ci.